tyrosine has been researched along with edotreotide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bale, R; Decristoforo, C; Dobrozemsky, G; Gabriel, M; Heute, D; Kendler, D; Kovacs, P; Uprimny, C; Virgolini, IJ; Von Guggenberg, E | 1 |
| Combs, SE; Debus, J; Dittmar, A; Dittmar, JO; Giesel, FL; Haberkorn, U; Habermehl, D; Kratochwil, C; Rieken, S; Welzel, T | 1 |
1 trial(s) available for tyrosine and edotreotide
| Article | Year |
|---|---|
68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT.
Topics: Adult; Aged; Female; Gallium Radioisotopes; Humans; Male; Middle Aged; Octreotide; Positron-Emission Tomography; Prospective Studies; Radionuclide Imaging; Receptors, Somatostatin; Tomography, X-Ray Computed; Tyrosine | 2007 |
1 other study(ies) available for tyrosine and edotreotide
| Article | Year |
|---|---|
First intraindividual comparison of contrast-enhanced MRI, FET- and DOTATOC- PET in patients with intracranial meningiomas.
Topics: Adult; Aged; Contrast Media; Female; Humans; Magnetic Resonance Imaging; Male; Meningeal Neoplasms; Meningioma; Middle Aged; Neuroimaging; Octreotide; Positron-Emission Tomography; Radiopharmaceuticals; Tyrosine | 2017 |